Related Experiment Video
Updated: Jul 15, 2026
09:27
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
A new era in HIV vaccine development
Chuen-Yen Lau1, Peter P Velasco, Margaret I Johnston
1Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700 B Rockledge Dr., Bethesda, MD 20817, USA. lauc@niaid.nih.gov
Expert Review of Anti-Infective Therapy
|April 4, 2007
Summary
Despite decades of research and available treatments, the human immunodeficiency virus (HIV) epidemic persists. The development of an effective HIV vaccine remains a critical, ongoing challenge, requiring sustained public and private sector collaboration.
Area of Science:
- Immunology
- Virology
- Public Health
Background:
- Since the identification of human immunodeficiency virus (HIV) in 1984, extensive research has advanced understanding of HIV disease and pathogenesis.
- Over two dozen HIV treatments are licensed in the USA, yet the global epidemic remains a significant public health concern.
- Early pharmaceutical industry involvement in HIV vaccine development waned as initial expectations for rapid success diminished.
Purpose of the Study:
- To review the historical trajectory and current landscape of HIV vaccine research.
- To highlight the evolving roles of public and private sectors in addressing the challenges of HIV vaccine development.
- To emphasize the continued reliance on scientific creativity and collaborative efforts for progress.
Main Methods:
- This review synthesizes information from investigator-initiated research and public health initiatives.
- It examines the historical engagement of the pharmaceutical industry and subsequent shifts in private investment.
- The analysis considers the public sector's strategies to foster industry collaboration and support academic research.
Main Results:
- Investigator-initiated research has significantly contributed to understanding HIV.
- The global HIV epidemic continues despite the availability of numerous therapeutic drugs.
- Public sector initiatives have been crucial in maintaining momentum in HIV vaccine research by engaging industry and supporting academia.
Conclusions:
- The development of a safe and effective HIV vaccine is a complex and ongoing endeavor.
- Sustained progress in HIV vaccine research necessitates creative scientific inquiry and diverse collaborations.
- Continued investment and strategic partnerships between public and private entities are essential to overcome the challenges of the HIV epidemic.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Related Concept Videos
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...